Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antimicrobial Respirator Mask Protects Surgical Teams

By HospiMedica International staff writers
Posted on 03 May 2011
A single-use, N95 grade surgical respirator for use by health care personnel protects against microorganisms, body fluids, and particulate material.

The SpectraShield 9500 surgical respirator offers superior filtration with N95 performance-- blocking at least 95% of dust particles--exceeds current guidelines for protection against infectious microbial threats such as avian influenza, severe acute respiratory syndrome (SARS), and tuberculosis. More...
The technology is based on an antimicrobial agent embedded into the fiber that kills 99.99% of three types of bacteria (Streptococcus pyogenes, Methicillin-resistant Staphylococcus aureus (MRSA), and Haemophilus influenzae).The embedded agent, called the Fosshield fiber system, also reduces mask odor caused by bacterial growth, and the surgical respirator continuously self-sanitizes itself for extended use.

Fosshield technology permanently embeds a nontoxic active silver and copper antimicrobial agent into the fibers of the material, causing bacteria to become unable to multiply on the outer layers of the mask, nor penetrate it over time. The Fosshield fiber system was developed in a collaborative research and development relationship with Foss Manufacturing (Hampton, NH, USA), the owner of the technology, in return for exclusive rights to use Fosshield in all textile-based healthcare products. The SpectraShield 9500 surgical respirator is a product of Nexera Medical (Richmond, Canada), and has been approved by the US Food and Drug Administration (FDA).

"Nexera developed this technology in response to existing health threats and the possibility of new strains of harmful microorganisms,” said Paul Sallarulo, president and CEO of Nexera. "We understand the need for governments and public health officials to have access to cutting edge technology that will help them prepare for and respond to future disease outbreaks and/or pandemics.”

N95 surgical respirators are different from regular facemasks, which are designed to help block large-particle droplets, splashes, sprays, or splatter that may contain viruses and bacteria from reaching the mouth and nose. They are not designed to block particles transmitted by coughs, sneezes, or certain medical procedures, nor do they provide complete protection from germs and other contaminants due to the loose fit between the surface and the face. N95 designation means that the respirator blocks at least 95% of very small particles, exceeding the capabilities of regular facemasks. Even a properly fitted N95 respirator, however, does not eliminate the risk of infection, illness, or death.

Related Links:
Nexera Medical
Foss Manufacturing



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.